SIGNET: protocol for a multicentre, single-blind prospective, group sequential, randomised controlled trial to evaluate the benefits of a single dose of simvastatin given to potential organ donors declared dead by neurological criteria on outcomes in organ recipients
Authors:
- Amy EvansAEAmy Evans
- Phil MawsonPMPhil Mawson
- Helen ThomasHTHelen Thomas
- Katie KeenKKKatie Keen
- Christopher Je WatsonCWChristopher Je Watson
- Daniel Francis McAuleyDMDaniel Francis McAuley
- Guy A MacGowanGMGuy A MacGowan
- Neil S SheerinNSNeil S Sheerin
- Andrew FisherAFAndrew Fisher
- James ShawJSJames Shaw
- Hilary YatesHYHilary Yates
- Andrea FallowAFAndrea Fallow
Open Access
Abstract
Introduction Successful organ transplantation in patients with end-stage organ failure improves long-term survival, improves quality of life and reduces costs to the NHS. Despite an increase in the number of deceased organ donors over the last decade, there remains a considerable shortfall of suitable organs available for transplantation. Over half of UK donors are certified dead by neurological criteria following brain stem compression, which leads to severe physiological stress in the donor, combined with a hyperinflammatory state. Brain stem death-related dysfunction is an important reason for poor organ function and hence utilisation. For example, more than 30% of donation after brain stem death cardiac transplant recipients need short-term mechanical cardiac support, reflecting donor heart dysfunction. A small, randomised study previously showed improved outcomes for cardiac transplant recipients if the donor was given simvastatin. SIGNET takes inspiration from that study and hypothesises a potential reduction in damage to the heart and other organs during the period after diagnosis of death and prior to organ retrieval in donors that receive simvastatin. Methods and analysis SIGNET is a multicentre, single-blind, prospective, group sequential, randomised controlled trial to evaluate the benefits of a single high dose of simvastatin given to potential organ donors diagnosed dead by neurological criteria on outcomes in all organ recipients. The trial will run across a minimum of 89 UK sites with a recruitment target of 2600 donors over 4 years. Ethics and dissemination SIGNET received a favourable opinion from the London, Queen Square Research Ethics Committee (Ref: 21/LO/0412) and following approval of substantial amendment 1 in January 2023, the current protocol is version 2 (7 December 2022). Substantial amendment 1 clarified consent procedures and added additional sites and prescribers. Findings from the study will be publicly available and disseminated locally and internationally through manuscript publications in peer-reviewed journals and conference presentations at national and international platforms. Trial registration number ISRCTN11440354Keywords
Funding Information
- Health Technology Assessment Programme (NIHR131124)
This publication has 13 references indexed in Scilit:
- Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical TrialTransplantation, 2022
- The impact of severe acute kidney injury requiring renal replacement therapy on survival and renal function of heart transplant recipients – a UK cohort studyTransplant International, 2020
- Donor Simvastatin Treatment in Heart TransplantationCirculation, 2019
- ISHLT Primary Graft Dysfunction Incidence, Risk Factors, and Outcome: A UK National StudyTransplantation, 2019
- Socioeconomic Deprivation and Survival After Heart Transplantation in EnglandCirculation: Cardiovascular Quality and Outcomes, 2016
- Inflammatory Signalling Associated with Brain Dead Organ Donation: From Brain Injury to Brain Stem Death and Posttransplant Ischaemia Reperfusion InjuryJournal of Transplantation, 2013
- Donor Simvastatin Treatment Abolishes Rat Cardiac Allograft Ischemia/Reperfusion Injury and Chronic Rejection Through Microvascular ProtectionCirculation, 2011
- Health-Related Quality of Life in Long-Term Survivors After Heart and Lung Transplantation: A Prospective Cohort StudyTransplantation, 2010
- Increased plasma interleukin-6 in donors is associated with lower recipient hospital-free survival after cadaveric organ transplantation*Critical Care Medicine, 2008
- Pulmonary Transplantation: the role of brain death in donor lung injuryTransplantation, 2003